Keywords
Abstract
Background: Rational drug prescription (RDP) is one of the main components of the healthcare systems. Irrational prescribing can bring about numerous negative consequences for the patients and governmental agencies. This study aims to analyze the involvement of stakeholders in rational drug prescribing, their position (opponent or proponent), and the rationale behind it.
Methods: This was a qualitative study conducted in 2019. Semi-structured face-to-face interviews were conducted with 40 stakeholders. Purposive and snowball sampling techniques with maximum heterogeneity were adopted to select the interviewees. Data was analyzed by MAXQDA software using thematic approach.
Results: Iranian Food and Drug Administration employs the highest authority on the rational prescribing policy. Although the Ministry of Health and Medical Education, the Social Security Organization as one of the main health insurance organizations, pharmaceutical companies, and the Medical Council of the Islamic Republic of Iran, are among agencies that have great authority to improve rational prescribing, they fail to act professionally as they have conflicting interests. Remarkably, the Iran Food and Drug Administration, insurance organizations, family physicians, and patients, highly support the rational prescribing policy while the pharmaceutical companies display the least support for it.
Conclusions: To make the prescription and using drugs more rational, policy makers should focus on different sources of conflicts of interest that different actors have. They should devise legal, behavior and financial policies accordingly to lessen or at least neutralize these conflicting interests, otherwise achieving RDP would be impossible in short and long terms.
References
Dong, L., H. Yan, and D. Wang, Drug prescribing indicators in village health clinics across 10 provinces of Western China. Family practice, 2011. 28(1): p. 63-67.
Calikoglu, E., et al., Rational drug use and prescribing behavior of family physicians in Erzurum, Turkey. Nigerian Journal of Clinical Practice, 2019. 22(5): p. 626-632.
Mamo, D.B. and B.K. Alemu, Rational drug-use evaluation based on World Health Organization core drug-use indicators in a tertiary referral hospital, Northeast Ethiopia: a cross-sectional Study. Drug, Healthcare and Patient Safety, 2020: p. 15-21.
Dessie, B., et al., Practice towards rational drug use at Finotselam and Asirade Zewudie Hospitals based on WHO core drug use indicators, Northwest Ethiopia. The Scientific World Journal, 2020. 2020.
Ahmed, S.M. and Q.S. Islam, Availability and rational use of drugs in primary healthcare facilities following the national drug policy of 1982: is Bangladesh on right track? Journal of health, population, and nutrition, 2012. 30(1): p. 99.
Haghighatpanah, M., et al., Study on prescribing pattern of anti-diabetic drugs among type 2 diabetes patients with complication in South Indian teaching hospital. morbidity and mortality, 2016. 9: p. 11.
Jin, G., et al., Prescribing patterns of encounters in fourteen general practice clinics in rural Beijing: a cross-sectional study. BMC health services research, 2019. 19: p. 1-12.
Raveh, D., et al., Longitudinal surveillance of antibiotic use in the hospital. Qjm, 2001. 94(3): p. 141-152.
Bae, E.Y. and E.K. Lee, Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea. Value in Health, 2009. 12: p. S36-S41.
Hakoum, M.B., et al., Reporting of financial and non-financial conflicts of interest by authors of systematic reviews: a methodological survey. BMJ open, 2016. 6(8): p. e011997.
Hill, J.C., et al., Development and initial cohort validation of the Arthritis Research UK Musculoskeletal Health Questionnaire (MSK-HQ) for use across musculoskeletal care pathways. BMJ open, 2016. 6(8): p. e012331.
Stuckler, D., S. Basu, and M. McKee, Global health philanthropy and institutional relationships: how should conflicts of interest be addressed? PLoS Medicine, 2011. 8(4): p. e1001020.
McCrary, S.V., et al., A national survey of policies on disclosure of conflicts of interest in biomedical research. New England Journal of Medicine, 2000. 343(22): p. 1621-1626.
Frolic, A. and P. Chidwick, A pilot qualitative study of" conflicts of interests and/or conflicting interests" among Canadian bioethicists. Part 1: Five cases, experiences and lessons learned. HEC F., 2010. 22: p. 5.
Kilic, B., et al., Health policy analysis for prevention and control of cardiovascular diseases and diabetes mellitus in Turkey. International journal of public health, 2015. 60: p. 47-53.
Sinnott, S.-J., et al., The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis. PloS one, 2013. 8(5): p. e64914.
Bazyar, M., et al., Stakeholders analysis of merging social health insurance funds in Iran: what kind of interests they may gain or lose? The International journal of health planning and management, 2019. 34(1): p. 157-176.
Joudaki, H., et al., Improving fraud and abuse detection in general physician claims: a data mining study. International journal of health policy and management, 2016. 5(3): p. 165.
Adebayo, E. and N. Hussain, Pattern of prescription drug use in Nigerian army hospitals. Annals of African medicine, 2010. 9(3).
Ikegami, N. and J.C. Campbell, Health Care Reform In Japan: The Virtues of Muddling Through: Tops in equality of access, among the lowest in health spending, Japan nevertheless has important problems to solve—gradually. Health affairs, 1999. 18(3): p. 56-75.
Wroe, J., How can the media be best used to influence the diabetes policy makers? Practical Diabetes International, 2006. 23(4): p. 178-182.
Rosselli R, Martini M, Fluad Effect Working group, Bragazzi NL, Watad A. The Public Health Impact of the So-Called ‘‘Fluad Effect’’ on the 2014/2015 Influenza Vaccination Cam- paign in Italy: Ethical Implications for Health-Care Workers and Health Communication Practitioners. Advances Experim Med Biol 2017;973:125—34.
Orsini D, Bianucci R, Galassi FM, Lippi D, Martini M. Ethics Med Public Health. Vaccine hesitancy, misinformation in the era of Covid-19: Lessons from the past; 2022 Oct;24:100812. doi: 10.1016/j.jemep.2022.100812. Epub 2022 Jun 13.